Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status:
Completed
Trial end date:
2018-09-04
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dasatinib works in treating patients with glioblastoma
multiforme or gliosarcoma that has come back. Dasatinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.